The Select Cyclooxygenase-2 Inhibitor Celecoxib Reduced the Extent of Atherosclerosis in Apo E-/- Mice

Journal of Surgical Research

Volumn 146, Issue 1, 2008, Pages 135-142

  Jacob, Shushan ^a   Laury Kleintop, Lisa ^b   Lanza Jacoby, Susan ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

adhesion molecules; apo E mice; atherosclerosis; cyclooxigenase 2; cyclooxygenase 2 inhibitors

Indexed keywords

APOLIPOPROTEIN E; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; PROSTAGLANDIN E2; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG EFFECT; DRUG INHIBITION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ILEUM; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRAZOLES; SULFONAMIDES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 41149163377     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.04.040     Document Type: Article

References (36)

1. Ross R. The pathogenesis of atherosclerosis: Perspective for the 1990s. Nature 362 (1993) 801
2. Alexander R.W. Inflammation and coronary artery disease. N Engl J Med 331 (1994) 4687
3. Mitchell J.A., and Warner T.D. COX isoforms in the cardiovascular system: Understanding the activities of the non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 5 (2006) 75
4. van der Wal A.C., Becker A.E., van der Loos C.M., et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89 (1994) 36
5. Pratico D., and FitzGerald G.A. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem 271 (1996) 8919
6. Fukunaga M., Makita N., Roberts L.J., et al. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol 264 (1993) C1619
7. Serhan C.N. Signalling the fat controller. Nature 384 (1996) 23
8. Baker C.S.R., Hall R.J.C., Evans T.J., et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and co-localizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 19 (1999) 646
9. Schonbeck U., Sukhova G.K., Graber P., et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 (1999) 1281
10. Hong B.K., Kwon H.M., Lee B.K., et al. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 41 (2000) 82
11. Belton O., Byrne D., Kearney D., et al. Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840
12. Stemme V., Swedenborg J., Claesson H., et al. Expression of cyclooxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 20 (2000) 146
13. Pratico D., Tillmann C., Zhang Z.B., et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 98 (2001) 3358
14. Burleigh M.E., Babaev V.R., Oates J.A., et al. Cyclooxygenase-2 promotes early atherosclerosis lesion formation in LDL receptor-deficient mice. Circulation 105 (2002) 1816
15. Burleigh M.E., Babaev V.R., Yancey P.G., et al. Cyclooxygenase-2 promotes early atherosclerosis lesion formation in Apo E-/- deficient and C57BL/6 mice. J Mol Cell Card 39 (2005) 443
16. Olesen M., Kwong E., Mezli A., et al. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J 36 (2002) 362
17. Rott D., Zhu J., Burnett M.S., et al. Effects of MF-tricyclic, a selective cyclooxygenase 2 inhibitor, on atherosclerosis progression and susceptility to cytomegalovirus replication in apoprotein-E knockout mice. J Am Coll Cardiol 41 (2003) 1812
18. Belton O.A., Duffy A., and Toomey S. Cyclooxygenase isoforms and platelet wall interations in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108 (2003) 3017
19. Lanza-Jacoby S., Miller S., Flynn J., et al. The cyclooxygenase (COX)-2 inhibitor, celecoxib, prevents the development of mammary tumors in HER-2/neu mice. Cancer Epidemiol Biomarkers Prev 12 (2003) 1486
20. Beckstead H.J., Stenberg P.E., McEver R.P., et al. Immunohistochemical localization of membrane and α-granule proteins in human megakaryocytes: Application to plastic embedded bone marrow biopsy specimens. Blood 67 (1986) 285
21. Gross S., Tilly P., Hentsch D., et al. Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 204 (2007) 311
22. Grosch S., Tegeder I., Niederberger E., et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the select COX-2 inhibitor celecoxib. FASEB J 15 (2001) 2742
23. Davies N.M., McLachlan A.J., Day R.O., et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclooxygenase-2 inhibitor. Clin Pharmcokinet 38 (2000) 225
24. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 120
25. King V.L., Trivedi D.B., Gitlin J.M., et al. Selective cyclooxygenase-2 inhibiton with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 26 (2006) 1137
26. Burleigh M.E., Babaev V.R., Patel M.B., et al. Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apo E-null mice. Biochem Pharmacol 70 (2005) 334
27. Bea F., Blessing E., Bennett B.J., et al. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 60 (2003) 198
28. Nakashima Y., Raines E.W., Plump A., et al. Up-regulation of VCAM-I and ICAM-1 at Atherosclerosis prone sites on the endothelium in the ApoE- Deficient mouse. Arteriosclerosis Thromb Vasc Biol 18 (1998) 842
29. Pei H., Wang Y., Miyoshi T., et al. Direct evidence for a crucial role of the arterial wall in control of atherosclerosis susceptibility. Circulation 114 (2006) 2382
30. Tous M., Ferre N., Vilella E., et al. Aspirin attenuates the initiation but not the progression of atherosclerosis in deficient mice fed a high-fat, high-cholesterol diet. Basic Clin Pharmacol Toxicol 95 (2004) 15
31. Bailey J.M., and Butler J. Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation. Atherosclerosis 17 (1973) 515
32. Hajjar D.P., and Pomerantz K.B. Signal transduction in atherosclerosis: Integration of cytokines and the eicosanoid. FASEB J 6 (1992) 2933
33. Menez E.J., Burtscher H.Y., and Kolarz G. Inhibition of cytokine production and adhesion molecule expression by ibuprofen is without effect on transendothelial migration of monocytes. Inflammation 23 (1999) 275
34. Gonzalez-Alvaro C., Munoz C., Garcia-Vicuna R., et al. Interference of nonsteroidal anti-inflammatory drugs with very late activation antigen 4/vascular cell adhesion molecule-1 mediated lymphocyte-endothelial cell adhesion. Arthritis Rheum 41 (1998) 1677
35. Sakai A. Diclofenac inhibits endothelial cell adhesion molecule expression induced with lipopolysaccharide. Life Sci 58 (1996) 2377
36. Miyamoto K., Miyake S., Mizuno M., et al. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 129 (2006) 1984